Zentalis Pharmaceuticals (ZNTL) Research & Development (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Research & Development of $28.7 million for Q1 2026, up 5.39% year-over-year from $27.2 million in Q1 2025, and down 2.62% quarter-over-quarter from $29.5 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Research & Development (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $28.7 million for Q1 2026.
- In Q1 2026, Research & Development rose 5.39% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $108.8 million (down 25.21% YoY), while the FY2025 annual figure was $107.3 million, down 36.05% from the prior year.
- Research & Development for Q1 2026 stood at $28.7 million, down from $29.5 million in the prior quarter.
- The five-year high for Research & Development was $51.6 million in Q4 2023, with the low at $23.0 million in Q3 2025.
- The 5-year median for Research & Development is $42.2 million (2022), against an average of $39.2 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development gained 26.94% in 2023, then plunged 45.05% in 2025.
- Zentalis Pharmaceuticals' Research & Development stood at $40.6 million in 2022, then increased by 26.94% to $51.6 million in 2023, then sank by 36.05% to $33.0 million in 2024, then slipped by 10.57% to $29.5 million in 2025, then retreated by 2.62% to $28.7 million in 2026.
- Business Quant data shows ZNTL's Research & Development at $28.7 million in Q1 2026, $29.5 million in Q4 2025, and $23.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 35.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.16 Mn |
| Mar 31, 2026 | 28.72 Mn |
| Dec 31, 2025 | 29.49 Mn |
| Sep 30, 2025 | 22.95 Mn |
| Jun 30, 2025 | 27.61 Mn |
| Mar 31, 2025 | 27.25 Mn |
| Dec 31, 2024 | 32.97 Mn |
| Sep 30, 2024 | 36.82 Mn |
| Jun 30, 2024 | 48.39 Mn |
| Mar 31, 2024 | 49.59 Mn |
| Dec 31, 2023 | 51.56 Mn |
| Sep 30, 2023 | 46.77 Mn |
| Jun 30, 2023 | 42.68 Mn |
| Mar 31, 2023 | 48.58 Mn |
| Dec 31, 2022 | 40.62 Mn |
| Sep 30, 2022 | 42.18 Mn |
| Jun 30, 2022 | 43.83 Mn |
| Mar 31, 2022 | 46.11 Mn |
| Dec 31, 2021 | 38.44 Mn |
| Sep 30, 2021 | 54.00 Mn |